Inspra治疗高血压疗效怎么样呢？

It is used to treat congestive heart failure and hypertension after acute myocardial infarction. So, how effective is Inspra in treating hypertension?

The therapeutic effect of Inspra in treating high blood pressure:

For patients with acute myocardial infarction who have reduced left ventricular transfusion fraction (LVEF) and signs of heart failure, adding Inspra to standard treatment can significantly reduce early all-cause mortality. 

The research team investigated the impact of the selective aldosterone blocker Inspra on 30-day mortality after randomization in 6,632 patients participating in the Inspra Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). The trial found that after an average follow-up of 16 months, Inspra reduced patients' all-cause mortality by 15% compared with traditional treatment alone.

All patients had LVEF equal to or less than 40% and had clinical signs of heart failure. Treatment with Inspra 25 mg/day or placebo was initiated an average of 7.3 days after acute myocardial infarction. The primary endpoint was all-cause mortality, and the composite endpoint was the time to death from cardiovascular causes or hospitalization for a cardiovascular event. 

The researchers found that 30 days after randomization, Inspra reduced the absolute risk of all-cause mortality by 1.4% compared with placebo (3.2% vs. 4.6% for Inspra and placebo-treated patients, P=0.004) and reduced the risk of cardiovascular mortality/cardiovascular hospitalization by 1.3%, from 9.9% to 8.6% (P=0.074). In addition, the relative risk of cardiovascular mortality was reduced by 32%, and the risk of sudden death was reduced by 37%. 

For patients with left ventricular systolic dysfunction and signs of heart failure, treatment should be started in the hospital when hemodynamics are stable after acute myocardial infarction, and Inspra treatment should be continued in addition to ACE inhibitors or angiotensin II receptor blockers, and beta-blockers.